The Ca2+-dependent cell-cell adhesion system (CDS) is thought to be essential for the formation and maintenance of cell adhesion in a wide variety of tissues. Previous studies suggested that CDS has some cell-type specificity; for example, the monoclonal antibody ECCD-1 selectively recognizes CDS of certain epithelial tissues in mouse embryos but not nervous tissues. In the present study, we have obtained a monoclonal antibody, designated NCD-1, that disrupts connections between brain cells of mouse embryos. A series of experiments suggested that NCD-1 specifically recognizes CDS. We then determined the distribution of the NCD-1 antigen in various mouse tissues. NCD-1 reacted with cells of the following tissues and cell lines: nervous tissues from various sources, lens, striated muscle, cardiac muscle, glioma G26-20, adrenocortical tumor Y1, and melanoma B16. None of these cells reacted with ECCD-1, and the cells reactive with ECCD-1 did not react with NCD-1. There was also a class of cells that did not react with either ECCD-1 or NCD-1. These results suggest that cells in the body can be classified into at least three groups containing CDS of differing specificities. A map of the tissue localization of these different classes of CDS also suggests that the expression of cell-type-specific cell adhesion molecules in each tissue plays a crucial role in adhesion between the same cell types and segregation of different cell types in processes essential for animal morphogenesis.
dent cell-cell adhesion system (CDS) are thought to be particularly important in initiation and maintenance of cell adhesion in various tissues, since inhibition of the CDS results in disruption of cell-cell adhesion, affecting embryonic morphogenesis (1) (2) (3) . While CDS is present in a wide variety of tissues, an interesting property of CDS is its cell-type-specific function (4) . We have previously shown that when two different types of cells such as teratocarcinoma and fibroblastic cells are combined, they cannot cross-adhere to one another by CDS, suggesting that the CDS in these two cell types is distinct in specificity (5) . This hypothesis was later confirmed with the monoclonal antibody ECCD-1, which was raised against the CDS of teratocarcinoma cells (6) .
Studies on the binding of ECCD-1 to various cells of mouse embryos showed that its target molecules are detected in all the cells of early embryo (2, 6) . However, during development they are lost from many tissues such as connective tissues and brain, although they persist in a number of types of epithelial cell in various organs (6) . Thiery et al. (7) performed a detailed analysis in chicken embryos of the tissue distribution of liver cell adhesion molecule (L-CAM), a molecule equivalent to the antigen of ECCD-1 (8) . They found that it is present in the ectoderm of early embryos but disappears from mesodermal cells at the stage of gastrulation and from nervous tissues at the stage of invagination of the neural plate. Thus, disappearence of L-CAM seems to be correlated with certain events in morphogenesis (9) .
In the present series of studies, we attempt to characterize the CDS in cells that do not react with ECCD-1. For this purpose, we obtained a monoclonal antibody termed NCD-1 that reacts with CDS in brain cells, and then we analyzed the tissue distribution of its antigens. The results show that the antigens of ECCD-1 and NCD-1 are expressed in completely different cell populations. On the basis of this tissue distribution pattern of CDS, we discuss a general scheme of involvement of this adhesion system in morphogenetic processes in animal development.
MATERIALS AND METHODS
Cell Lines. Teratocarcinoma AT805 (5), adrenocortical tumor Y1 (10), neuroblastoma Neuro 2a (11) , melanoma B16 (12) , and PSA5-E (13) were cultured in a 1:1 mixture of Dulbecco's modified Eagle's minimal essential medium and Ham's F-12 medium supplemented with 10% fetal calf serum (DH10F). Glioma G26-20 (14) was cultured in Ham's F-12 medium with 10% fetal calf serum. Myeloma P3-X63-Ag8-U1 (15) and hybridoma were also maintained in DH10F.
Primary Cell Cultures. Various organs were isolated from fetal ICR mice (Shizuoka Laboratory Animal Center) of the following ages post coitus: whole brain of 10.5 days; otic vesicle of 10.5 days; lens and epidermis of 11.5 days; dorsal root ganglia and heart of 12 days; spinal cord, lung, and liver of 13 days; skeletal muscle, salivary gland, neurohypophysis, and adenohypophysis of 18 days. Pancreas, stomach, and thyroid were obtained from newborn ICR mice. Mammary gland and endothelium of common carotid artery were isolated from adult ICR mice. Adult lens and skeletal muscle were also used.
These tissues were dissociated by treatment with trypsin, collagenase, or both and cultured with DH1OF in 3.5-cm-diameter Falcon dishes coated with collagen. These cultures were usually prepared 1 or 2 days before use. Clonal cultures of skeletal muscles were prepared by T. Kagawa (Toneyama National Hospital) as described previously (16) and used after 9 days in culture.
Preparation of Hybridomas and Monoclonal Antibodies. A rat (Wistar strain, Shizuoka Laboratory Animal Center) was immunized by an intraperitoneal injection of whole brain tissues obtained from 30 ICR mouse fetuses of 9.5 days post coitus. These tissues were homogenized during injection by passage through the injection needle. After three weeks, a booster injection of the same antigens was performed three times at 11-day intervals, and, 3 days after the last injection, spleen cells of this animal were fused with mouse myeloma P3-X63-Ag-U1 cells. For screening hybridomas, we added their culture fluids to monolayer cultures of brain cells obtained from mouse fetuses of 10.5 days post coitus, and we examined for induction of morphological changes in brain cell colonies by microscopy.
For production of antibodies, hybridomas were either cultured in serum-free medium as described by Murakami et al. (17) For cytotoxicity tests using suspended cells, 106 cells were first incubated in 1 ml of rat hybridoma ascites fluid diluted 1 to 100-200 with H-DHM at 4°C for 60 min. After removal of this solution by centrifugation, cells were resuspended in 1 ml of the above absorbed complement solution and incubated at 37°C for 60 min. The cells were sedimented and incubated with 0.1% trypan blue in Hanks' solution for 5 min in an ice bath for determination of percent lysed cells. When monolayer cultures were used for this assay, we incubated cells with 1 ml per 3.5-cm dish of rat hybridoma ascites fluid diluted 1 to 100-200 with the above complement solution at 37°C. After appropriate incubation (usually 4 hr maximum), the nonlysed cells were counted in randomly selected areas of culture dishes under a phase microscope and compared to the original cell number in the same area to calculate viability. As a control, heat-inactivated nonimmu- formed compact clusters in which cells were densely packed when cultured overnight ( Fig. 1 a and c) . When the culture medium contained NCD-1, the brain cells did not form compact clusters but instead formed clusters with looser cellcell connections ( Fig. 1 b and d) .
Because these observations suggested that NCD-1 affects cell-cell adhesion, we more quantitatively analyzed the effect of this antibody on cell-cell adhesion. It has been shown that cells of the nervous system as well as of other tissues contain two distinct cell-cell adhesion systems, CDS and a Ca2+-independent system (CIDS) (4, 18) . Treatment of cells with 0.01% trypsin in the presence of Ca2+ (TC treatment) leaves only CDS intact, while treatment with a low concentration (0.0001%) of trypsin in the absence of Ca2+ or in the presence of EGTA (LTE treatment) leaves only CIDS intact. Treatment of cells with 0.01% trypsin in the presence of EGTA (TE treatment) inactivates both adhesion systems.
We examined whether NCD-1 inhibits aggregation of brain cells dissociated by any of the above trypsin treatments. We found that aggregation of TC-treated cells was inhibited by this antibody in a concentration-dependent manner but that of LTE-treated cells was not (Fig. 2) . ECCD-1 did not affect aggregation of brain cells.
The NCD-1 antibody belongs to the IgM class as judged by its molecular weight, and it displayed complement-dependent cytotoxicity for brain cells. When brain cells were subjected to the complement-dependent cytotoxicity test after different trypsin treatments, TC-treated cells were killed by NCD-1, but neither LTE-treated nor TE-treated cells were cytolyzed ( Table 1 ). All of these results suggest that NCD-1 specifically binds to components of CDS.
Effect of NCD-1 on a Glioma Cell Line. Cells of a glioma line G26-20 also reacted with NCD-1. As found with brain cells, aggregation of TC-treated G26-20 cells was inhibited by NCD-1 but that of LTE-treated cells was not (Fig. 2) . Complement-dependent cytotoxicity tests also showed that this antibody lyses TC-treated cells but not LTE-or TEtreated cells (Table 1) . These results further indicated that the target of NCD-1 is CDS. ECCD-1 showed no effect on aggregation of G26-20 cells. Our previous study showed that the monoclonal antibody ECCD-1, which recognizes CDS in teratocarcinoma cells, binds to its target molecules in a Ca2+-dependent manner. We thus tested NCD-1 for divalent cation dependence in its binding to cell surfaces by means of the complement-dependent cytolysis assay. The results showed that NCD-1 binds to cell surfaces only in the presence of Ca2' or Mn2+ (Fig.   3 ).
Cell-Type Specificity of NCD-1 Targets. We examined which cell types in mouse tissues are reactive with NCD-1, comparing them to the ECCD-1-sensitive cell types. For detecting NCD-1-sensitive cells we employed a complementdependent cytotoxicity test because this was found to be the most sensitive method for the present purpose. To identify ECCD-1-sensitive cells, we assayed the adhesion-blocking effect of this antibody (6) by adding it to monolayer cultures of cells. (Immunohistochemical staining was not sufficiently sensitive to detect binding of these antibodies, and ECCD-1 showed no cytotoxic effects.)
Primary cultures of cells obtained from various organs of fetal and adult mice were prepared. In cultures of brain cells obtained from 10.5-day fetuses in which multiple cell types were detected, most cells reacted with NCD-1 after incubation with complement for 4 hr (CI > 90), although cells with fine processes, probably neurons, tended to require longer incubation periods to be killed. Similar results were obtained with dorsal root ganglia (Fig. 4 a and b) and spinal cord. In these experiments, none of the cells in control plates, which contain complement and nonimmune rat serum, were significantly lysed during incubation, indicating that the observed cytotoxic effect was due to specific binding of NCD-1 to its antigen. In summary, all cells tested from nervous tissues (Fig. 4 c  and d) . Fibroblastic cells present in muscle tissues also did not react with NCD-1. None of the NCD-1-sensitive cells was found to react with ECCD-1. Aggregation of lens epithelial, Y1, and B16 cells dissociated by TC treatment was inhibited by NCD-1 but not by ECCD-1 (data not shown). (Other NCD-1-sensitive cells were not tested in this aggregation assay.)
Epithelial cells of the following tissues did not react with NCD-1, but their cell-cell adhesion was disrupted by ECCD-1: epidermis, mammary gland, liver, pancreas, stomach, salivary gland (Fig. 5 a and b) , thyroid, and adenohypophysis. Epithelial components of otic vesicle reacted with ECCD-1 (Fig. 5 c and d) , but some nonepithelial cells present in cultures of this tissue also reacted with NCD-1. (It was not determined whether these NCD-1-sensitive cells were genuine components of otic vesicle or derived from surrounding tissues.) One-cell and eight-cell stage (compacted) embryos and teratocarcinoma AT805 cells, which were previously shown to be sensitive to ECCD-1 (6), were resistant to NCD-1. Aggregation of these ECCD-1-sensitive cells dissociated by TC treatment was not inhibited by NCD-1 (data not shown).
Fibroblastic cells present in cultures of the above ECCD-1-sensitive tissues generally did not react with either ECCD-1 (see also ref. 6) or NCD-1. Endothelial cells of artery, neuroblastoma Neuro 2a cells, and PSA5-E cells, which were identified as visceral endoderm cells, were also resistant to both ECCD-1 and NCD-1.
DISCUSSION
CDS is present in a wide variety of cell types, probably in all kinds of cells that form solid tissues. Both NCD-1 and ECCD-1 antibodies inhibited cell-cell adhesion mediated by CDS of various tissues, but these two kinds of antibodies recognized distinct cell types, as schematically summarized in Fig. 6 . Some groups of cells, such as fibroblasts of various tissues and endothelial cells of blood vessels, did not react with either NCD-1 or ECCD-1. These results suggest that CDS should be divided into subclasses with different immunological specificity: an NCD-1-reactive type, an ECCD-1-reactive type, and a third, nonreactive, type. These subclasses of CDS are probably also distinct in functional specificity, that is, they may not be cross-reactive to each other in an aggregation assay, as has been shown by the lack of cellcell adhesion in a combination of teratocarcinoma CDS and fibroblast CDS (5) .
The antilens identified by NCD-1 and ECCD-1 showed similar Ca + sensitivity; they are both protected by Ca2+ against proteolysis and require Ca2' not only for expressing their activity but also for reacting to each antibody. Mn2+ was also effective in inducing binding of both of these antibodies to cell surfaces as found in the previous (6) and present experiments. These suggest that they have some common molecular structure. The target of ECCD-1 with such properties has already been identified (6) ; the major component of this target was a protein with a molecular weight of 124,000, termed "cadherin." Similar molecules were also identified by other groups (19) (20) (21) (22) Assuming that the targets of NCD-1 and ECCD-1 are related to each other (since both are involved in CDS), we call the hypothetical antigens of NCD-1 "N-cadherin" and the identified antigens of ECCD-1 "E-cadherin," thus functionally subdividing the term "cadherin" originally given to the latter antigens.
Is N-cadherin related to previously identified cell adhesion molecules? So far, at least three types of cell-cell adhesion molecules have been detected from nervous tissue by using monoclonal antibodies: N-CAM (and its related molecules) (24) , Ng-CAM (25) , and Li antigen (26) , all of which were reported to be involved in CIDS. Since CDS is a funcProc. NatL Acad ScL USA 82 (1985) tional system completely independent of CIDS (27) (28) (29) (7) . Similarly, in eye formation, the lens loses L-CAM during invagination. It is, therefore, possible that de novo expression of N-cadhemn may occur in these tissues at the invagination stage following disappearance of E-cadherin. The epidermis (ectoderm) from which the neural tube and lens originally arose continues to express L-CAM or E-cadherin. Thus, expression of new specific adhesion molecules in invaginating tissues may be an important factor for their separation from overlying ectoderm. To verify such a hypothetical mechanism of tissue separation, we must accumulate more information on the on-off of expression of various subclasses of cadherin molecules.
